ID   KOSC-2
AC   CVCL_1337
SY   KOSC2; KOSC-2 cl3-43; KOSC2CL343; Kobe university Oral Squamous Cell culture-2
DR   BTO; BTO:0005968
DR   CLO; CLO_0009947
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470801
DR   cancercelllines; CVCL_1337
DR   Cell_Model_Passport; SIDM00603
DR   CGH-DB; 371-2
DR   ChEMBL-Cells; CHEMBL3308750
DR   ChEMBL-Targets; CHEMBL1075481
DR   Cosmic; 753570
DR   Cosmic-CLP; 753570
DR   DepMap; ACH-001543
DR   DepMap; ACH-002260
DR   EGA; EGAS00001000978
DR   GDSC; 753570
DR   GEO; GSM827195
DR   GEO; GSM1670001
DR   IARC_TP53; 21439
DR   JCRB; JCRB0126.1
DR   LINCS_LDP; LCL-1227
DR   PharmacoDB; KOSC2_780_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1337
DR   PubChem_Cell_line; CVCL_1337
DR   Wikidata; Q54900341
RX   PubMed=8314315;
RX   PubMed=17599052;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 18.7 hours (PubMed=8314315).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Arg5Gln (c.14G>A); ClinVar=VCV000376520; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Glu40Gln (c.118G>C); ClinVar=VCV000376517; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52delinsProTer (c.154_155insCAT); Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.44%; Native American=0%; East Asian, North=72.8%; East Asian, South=22.55%; South Asian=0%; European, North=0%; European, South=3.2% (PubMed=30894373).
CC   Discontinued: DepMap; ACH-002260; true.
CC   Derived from site: In situ; Oral cavity, floor of mouth; UBERON=UBERON_0003679.
ST   Source(s): Cosmic-CLP; DepMap; JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9,12
ST   D18S51: 13
ST   D21S11: 29,31
ST   D3S1358: 15
ST   D5S818: 9
ST   D7S820: 10,11
ST   D8S1179: 13,16
ST   FGA: 21
ST   Penta D: 9,10
ST   Penta E: 15
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 15,17
DI   NCIt; C4041; Floor of mouth squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 36
//
RX   PubMed=8314315; DOI=10.1002/ijc.2910560226;
RA   Inagaki T., Matsuwari S., Takahashi R., Shimada K.-k., Fujie K.,
RA   Maeda S.;
RT   "Establishment of human oral-cancer cell lines (KOSC-2 and -3)
RT   carrying p53 and c-myc abnormalities by geneticin treatment.";
RL   Int. J. Cancer 56:301-308(1994).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//